FTRE Stock Forecast & Price Target

Fortrea Holdings is viewed constructively because its 3Q26 results showed improved execution, with management raising 2026 revenue guidance to $2.665 billion-$2.69 billion and adjusted EBITDA to $210 million-$218 million. The company’s outlook is supported by expanding margins from efficiency gains, operating leverage, and a better trial mix, while direct-fee margins have already expanded more than 200 bps year to date and cash flow and net leverage improved. Additional upside comes from a recovering biotech and large-pharma demand environment, plus the Worldwide Clinical Trials acquisition, which adds 200 beds, broadens CPS capabilities, and should convert pass-through work into higher-margin fee revenue over time.

Fortrea Holdings is facing a structurally cautious outlook because CRO demand can weaken if government regulation, macroeconomic softness, or biopharma capital constraints reduce outsourced clinical spending. The company also faces meaningful execution risk, since it does not expect a net bookings benefit and the one-time backlog adjustment implies less support from existing contracts, while inactive studies and scope changes highlight fragile near-term revenue visibility. Competitive pressure from larger CROs, customer preference shifts toward scale, and wage inflation from talent competition could further compress margins and make delivery of cost savings and operational improvements harder to achieve.